Peptide library / Cartalax

Cartalax

Cartalax is a synthetic tripeptide with the sequence Lys-Glu-Asp, commonly abbreviated KED.

Peptide & blend guide

The short version

Why people discuss it
Discussed for cartilage, joint and connective-tissue maintenance. Community interest does not establish benefit or a suitable treatment.
What it is
Cartalax is a synthetic tripeptide with the sequence Lys-Glu-Asp, commonly abbreviated KED.
Biggest caution
Laboratory or product-specific cartilage findings do not establish joint repair in people. Sequence verification, delivery, comparative evidence and long-term safety remain unresolved.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Sources report different amounts or schedules; the reference below is a named example, not a consensus.

Subcutaneous injection

Community reference · Not clinical guidance
Amount
2 mg
Frequency
Once daily
Duration / phase
10–20 days

Older short-course community convention. PeptideDosages starts at the same 2 mg but escalates to 5 mg and runs 8–12 weeks. Starting-dose agreement does not confirm the longer course. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library